Creo Medical Group PLC
LSE:CREO
Creo Medical Group PLC
LSE:CREO
Price:
36.5 GBX
Market Closed
Updated:
May 22, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
3.7
Current
3.4
Median
2.5
Industry
Higher
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=3.7
Enterprise Value
/
107.2m
Revenue
29.2m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| UK |
|
Creo Medical Group PLC
LSE:CREO
|
128.1m GBP | 3.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
179.1B USD | 4.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
142.6B USD | 18.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.9B USD | 6.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD | 4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
111.2B USD | 8.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68.2B USD | 4.1 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.8B EUR | 3.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
54.4B USD | 8.7 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
51.8B USD | 13.5 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.3B CNY | 9.8 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
3.2
2-Years Forward
EV/S
2.6
3-Years Forward
EV/S
2
You don't have any saved screeners yet
